Incyte announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an… read more.
New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. These data… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
Novo Nordisk announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from… read more.
MetaVia announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has… read more.
Johnson & Johnson announced the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the… read more.
United Therapeutics Corporation announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20,… read more.
Cytokinetics, Incorporated announced the presentation of new data reinforcing the clinical profile of Myqorzo (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations… read more.
argenx SE announced the FDA approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized… read more.
NICE(UK): Vorasidenib can be used as an option to treat grade 2 astrocytoma or oligodendroglioma in people 12 years and over when: i) the cancer has a susceptible… read more.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Mekinist. The marketing… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
